Chemotherapy for Poor-Risk Osteosarcoma
Author Information
Author(s): Michelagnoli M P, Lewis I J, Gattamaneni H R, Bailey C C, Lashford L S
Primary Institution: St James University Hospital, Leeds, UK
Hypothesis
The study evaluates the effectiveness and safety of a chemotherapy regimen combining ifosfamide, etoposide, and high-dose methotrexate for treating poor-risk osteosarcoma.
Conclusion
The chemotherapy regimen shows a promising response rate and a tolerable toxicity profile in children with poor prognosis osteosarcoma.
Supporting Evidence
- The majority of chemotherapy cycles were well tolerated.
- A partial response rate of 31% was observed after two cycles.
- An overall response rate of 62% was noted.
- Four patients were alive with no evidence of disease at 8–74 months.
Takeaway
Doctors tried a new medicine mix to help kids with a tough kind of bone cancer, and it worked pretty well without making them too sick.
Methodology
Fifteen patients received a combination of ifosfamide, etoposide, and high-dose methotrexate in a planned 21-day cycle, with assessments for toxicity and response.
Limitations
The study had a small sample size and was limited to patients with relapsed osteosarcoma.
Participant Demographics
Participants were children with relapsed osteosarcoma.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website